EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Fosfomycin monotherapy for the treatment of a complicated prostatic abscess caused by KPC-producing carbapenem-resistant Escherichia coli

Nguyen Thi Tuyen, Nguyen Sy Thau iD, Pham Thi Thanh Nhan, Nguyen Van Tuan, Nguyen Trong The iD

ASM Case Reports · 03.11.2026 · 2 (6)

DOI: 10.1128/asmcr.00112-26 ↗

Kurz gefasst

Fallbericht in der Zeitschrift ASM Case Reports, erschienen am 03.11.2026. Verfasst von Nguyen Thi Tuyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vietnamese-German Center for Medical Research (VG-CARE), 108 Military Central Hospital, Hanoi, Vietnam. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostatic abscess caused by carbapenem-resistant Escherichia coli (CREC) is an uncommon but serious infection with limited therapeutic options, particularly when prolonged antimicrobial therapy and oral step-down treatment are required. Evidence supporting fosfomycin monotherapy for prostatic abscess caused by CREC remains scarce. Case Summary A 67-year-old man with diabetes mellitus and prolonged corticosteroid exposure presented with severe sepsis secondary to a multiloculated prostatic abscess measuring 57.2 × 38.7 × 49.4 mm. Urine and abscess cultures yielded KPC-producing CREC susceptible to fosfomycin (MIC = 0.25 μg/mL) and amikacin. Because access to newer β-lactam/β-lactamase inhibitor agents was limited, treatment was initiated with intravenous fosfomycin plus amikacin. Amikacin was discontinued after 2 days because of nephrotoxicity, and therapy was successfully continued with intravenous fosfomycin monotherapy following transperineal ultrasound-guided abscess drainage. The patient received intravenous fosfomycin 6 g every 8 h for 21 days, followed by oral fosfomycin calcium 3 g every 24 h for 30 days, with complete clinical and radiological resolution, and no relapse during 6 months of follow-up.

Conclusion

Although the initial brief course of amikacin may have contributed to early bacterial clearance, the majority of treatment was administered as fosfomycin monotherapy after adequate source control. This case suggests that antibiotic susceptibility test-guided fosfomycin monotherapy, combined with adequate drainage, is a feasible treatment for prostatic abscesses caused by CREC, particularly in resource-limited settings.

Schlagwörter

Stichwörter der Autor:innen

Escherichia coliKPCcarbapenem-resistantfosfomycinprostatic abscess

Autor:innen und Institutionen

  • Vietnamese-German Center for Medical Research (VG-CARE), 108 Military Central Hospital, Hanoi, Vietnam.
  • Institute of Clinical Infectious Diseases, 108 Military Central Hospital, Hanoi, Vietnam.
  • Department of Functional Exploration, 108 Military Central Hospital, Hanoi, Vietnam.

ORCID-Profile: Nguyen Sy Thau, Nguyen Trong The

Zitieren

APA

Tuyen, N. T., Thau, N. S., Nhan, P. T. T., Tuan, N. V., & The, N. T. (2026). Fosfomycin monotherapy for the treatment of a complicated prostatic abscess caused by KPC-producing carbapenem-resistant Escherichia coli. ASM Case Reports, 2(6). https://doi.org/10.1128/asmcr.00112-26

Vancouver

Tuyen NT, Thau NS, Nhan PTT, Tuan NV, The NT. Fosfomycin monotherapy for the treatment of a complicated prostatic abscess caused by KPC-producing carbapenem-resistant Escherichia coli. ASM Case Reports. 2026;2(6). doi:10.1128/asmcr.00112-26

BibTeX
@article{Tuyen2026,
  author = {Tuyen, Nguyen Thi and Thau, Nguyen Sy and Nhan, Pham Thi Thanh and Tuan, Nguyen Van and The, Nguyen Trong},
  title = {Fosfomycin monotherapy for the treatment of a complicated prostatic abscess caused by KPC-producing carbapenem-resistant Escherichia coli},
  journal = {ASM Case Reports},
  year = {2026},
  volume = {2},
  number = {6},
  doi = {10.1128/asmcr.00112-26}
}
Kostenlos starten →